Overview

* Aurora fiscal Q2 2026 revenue misses analyst expectations despite 15% growth in medical cannabis

* Adjusted EBITDA for fiscal Q2 2026 grows 52% to C$15.4 mln

* Company maintains strong balance sheet with C$141.9 mln cash, debt-free cannabis business

Outlook

* Aurora expects Q3 2026 net revenue to grow, driven by 8%-12% increase in Global Medical Cannabis

* Company anticipates positive free cash flow in Q3 2026 due to improved operating cash use

* Aurora expects strong adjusted gross margins in cannabis business for Q3 2026

Result Drivers

* MEDICAL CANNABIS GROWTH - 15% YoY increase in medical cannabis revenue driven by sales in Australia, Germany, Poland, and the UK

* CONSUMER CANNABIS DECLINE - Decrease in consumer cannabis revenue due to focus on higher-margin medical products

* PLANT PROPAGATION REVENUE - 34% increase in plant propagation revenue from organic growth and expanded offerings

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss C$70.50 C$87.32

Revenue mln mln (4

Analysts

)

Q2 C$15.40

Adjusted mln

EBITDA

Q2 61%

Adjusted

Gross

Margin

Q2 C$51.80

Adjusted mln

Gross

Profit

Q2 Net -C$53.20

Income mln

from

Cont Ops

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Aurora Cannabis Inc ( ACB ) is C$7.85, about 18.2% above its November 4 closing price of C$6.42

* The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)